Market Overview

ACADIA Pharmaceuticals Q4 Earnings Preview


On Tuesday, ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.

Earnings and Revenue

ACADIA's per-share loss will be near 57 cents per share on sales of $44.3 million, according to Wall Street analysts.

ACADIA reported a per-share loss of 65 cents when it published results during the same quarter last year. Sales in that period totaled $11.9 million. If the company were to report inline earnings when it publishes results Tuesday, earnings would be down 10.77 percent. Sales would be up 270.51 percent from the year-ago period.

ACADIA's reported EPS has stacked up against analyst estimates in the past like this:


Quarter Q3 2017 Q2 2017 Q1 2017 Q4 2016
EPS Estimate -0.62 -0.72 -0.73 -0.65
EPS Actual -0.53 -0.55 -0.72 -0.65

Stock Performance

Over the past 52-week period, shares of ACADIA have declined 20.32 percent.

Analysts have adjusted their estimates higher for EPS and revenues over the past 90 days. Analysts seem to have settled on a Neutral rating with ACADIA Pharmaceuticals. The strength of this rating has maintained conviction over the past three months.

Conference Call

ACADIA is scheduled to hold a conference call at 4:00 p.m. ET and it can be accessed here:

Posted-In: Earnings News Previews Trading Ideas


Related Articles (ACAD)

View Comments and Join the Discussion!

Theravance Biopharma Q4 Earnings Outlook

Jazz Pharmaceuticals Q4 Earnings Outlook